Loading...
Rituximab (Rituxan) Therapy for Severe Thyroid-Associated Ophthalmopathy Diminishes IGF-1R(+) T Cells
CONTEXT: Rituximab depletes CD20(+) B cells and has shown potential benefit in thyroid-associated ophthalmopathy (TAO). The impact of rituximab on T cell phenotype in TAO is unexplored. OBJECTIVE: The objective of the study was to quantify the abundance of IGF-I receptor-positive (IGF-1R(+)) CD4 and...
Na minha lista:
| Udgivet i: | J Clin Endocrinol Metab |
|---|---|
| Main Authors: | , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Endocrine Society
2014
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4399483/ https://ncbi.nlm.nih.gov/pubmed/24670080 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1210/jc.2013-3207 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|